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I. Materials and methods 
 (A) All chemicals and solvents were purchased from commercial suppliers (Sigma Aldrich, 
Alfa Aesar, Fisher Scientific) and used without additional purification. The following proteins were 
purchased: Lysozyme (Sigma-Aldrich, product number: L6876), DNase I (GOLDBIO, catalog 
number D-300-5) and alcohol dehydrogenase (recombinant, from E. coli, Sigma Aldrich, product 
number: 49641). 
(B) 1H, 13C and 19F NMR spectra were recorded on a Varian Inova 300 MHz or 500 MHz, 
or Bruker Prodigy 400 MHz instrument, in CDCl3 and are referenced to the residual solvent peak. 
Data for 1H NMR are reported in the conventional form: chemical shift (δ ppm), multiplicity (d = 
doublet, dd = doublet of doublets, t = triplet, q = quartet, m = multiplet), coupling constant (Hz), 
integration. Data for 13C NMR are reported in terms of chemical shift (δ ppm), multiplicity (t = 
triplet, q = quartet).  
(C) Analytical high-performance liquid chromatography (HPLC) was carried out on an 
Agilent 1260 Infinity instrument using a Poroshell 120 Eclipse column (Agilent, XDB C18, 4.6 x 
5 mm, 2.7 µm) with H2O and acetonitrile as the mobile phase. All measurements were performed 
with an Agilent 1260 Infinity Diode Array Detector and the wavelength at 210 nm was recorded. 
HPLC method for screening: Begin with 28% acetonitrile, hold for 0.3 min, linear gradient to 100% 
acetonitrile after 1.2 min, hold for 0.3 min, return to 28% acetonitrile from 1.5 to 1.6 min., hold for 
0.75 min. Flowrate 2.5 mL/min. HPLC method for quantification: Begin with 10% acetonitrile, 
linear gradient to 75% acetonitrile after 7.5 min, linear gradient to 100% acetonitrile after 7.8 min, 
hold for 1.0 min, back to 10% acetonitrile from 8.8 to 8.9 min., keep for 1.4 min. Flowrate 
1.5 mL/min. HPLC method for the quantification of a-methylstyrene and trans-b-methylstyrene 
conversions: Begin with 20% acetonitrile, linear gradient to 50% acetonitrile after 6.5 min, linear 
gradient to 75% acetonitrile after 7.5 min, linear gradient to 100% acetonitrile after 8.8 min, hold 
for 2.0 min, return to 20% acetonitrile from 10.8 to 10.9 min., hold for 1.4 min. Flowrate 
1.5 mL/min. 
(D) Gas chromatography (GC) analyses were conducted with a Shimadzu GC-17A 
instrument equipped with a flame ionization detector using an Agilent J&W HP-5 column (30 m x 
0.32 mm, 0.25 µm film, part number 19091J-413) with helium as carrier gas. Injector temperature: 
250°C. Split mode with a split ratio of 5. Detector temperature: 300°C. Oven temperature: 90 °C 
hold 2 min, 6 °C/min to 100 °C, 40 °C/min to 280°C hold 1 min, 9.17 min total.  
(E) Chiral GC analysis was conducted with an Agilent 7820A instrument equipped with a 
flame ionization detector using an Agilent Cyclosil-B column (30 m x 0.32 mm, 0.25 µm film, part 
number 113-6632) with helium as carrier gas. Injector temperature: 200°C. Split mode with a split 
ratio of 5. Detector temperature: 300°C. Method for the separation of 2-phenylpropionaldehyde, 
oven temperature: Begin at 90 °C, 0.1 °C/min to 92.8 °C, 15 °C/min to 240 °C, hold 2 min. Method 
for the separation of 2-phenyl-1-propanol, oven temperature: Begin at 105 °C, 0.15 °C/min to 
109.5 °C, 40 °C/min to 240 °C, hold 2 min. Method for the separation of 1-phenyl-2-propanol, 
oven temperature: Begin at 80 °C, hold 2 min, 8 °C/min to 120 °C, 12 °C/min to 170 °C, 15 °C/min 
to 240 °C, hold 5 min. 
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(F) P450LA1 was cloned into a pET22b(+) vector containing a C-terminal 6xHis-tag. Gene 
and amino acid sequence of cytochrome P450LA1 monooxygenase (Uniprot ID: A0P0F6) which 


























































































II. General procedures 
 (A) Cloning and library creation. pET22b(+) was used as a cloning and expression vector 
for all enzymes and variants described in this study. The E. coli codon optimized P450LA1 gene 
(Uniprot ID: A0P0F6) was ordered from IDT containing a C-terminal 6xHis-tag. Random 
mutagenesis of P450's heme domain was performed by error-prone PCR using varying MnCl2 
concentrations. The resulting PCR products were digested with DpnI, purified by agarose gel 
electrophoresis and ligated into the pET22b(+) vector backbone by Gibson assembly (45). After an 
additional DNA purification step the plasmids were transformed via electroporation into E. cloni 
strain BL21(DE3). Site-saturation libraries were generated employing the “22c-trick” method (46). 
The PCR products were gel purified, digested with DpnI, ligated using the Gibson assembly Mix, 
and used to directly transform E. cloni strain BL21(DE3). 
(B) Expression of P450 libraries in 96-well plates. The expression and screening of P450 
variants was performed in 96-well plate format. Individual colonies from P450 libraries were 
cultivated in 500 µL of Terrific Broth medium (100 µg mL-1 ampicillin final concentration) for 
20 h at 37 °C, 250 rpm using humidity control. Expression cultures were inoculated with 50 µL of 
preculture into 610 µL of Terrific Broth medium (100 µg mL-1 ampicillin final concentration). The 
cultures were incubated for 4 h at 37 ºC, 250 rpm, then cooled on ice for 10 min before induction 
(0.2 mM IPTG, 0.5 mM aminolevulinic acid, final concentration). Induced cells were shaken for 
20 h at 25 ºC, 250 rpm. The cells were harvested (4500´g, 5 min, 4 ºC) and stored at -20 °C for 
three days. 
(C) Screening of random mutagenesis libraries using the Purpald assay.(47) Buffer 
(0.1 M NaH2PO4, pH 8.0, 0.15 M NaCl, 0.5% glycerol by weight, 1.0 mg/mL lysozyme, 0.2 mg/mL 
DNase, 300 µL/well) was added to the cell pellet and lysis was performed by incubating 4 h at 
4 °C, 150 rpm. The plate was centrifuged (4000´g, 4 °C, 10 min) and 100 µL of lysate were 
transferred with an automated liquid handling workstation to 96-well assay plates containing 5 µL 
styrene/DMSO stock solution and 100 µL NADH stock solution in buffer (10 mM styrene, 3.3 mM 
NADH final concentration). The plates were incubated for 2 h at 20 °C, 200 rpm. Purpald dissolved 
in 2 M NaOH (31 mM, 50 µL/well) was added and the plate was incubated for 30 min at room 
temperature. Aldehyde activity was analyzed by measuring the absorbance at 538 nm. 1500-2500 
variants were screened per generation. 
(D) HPLC screening of site-saturation libraries. Buffer (0.1 M NaH2PO4, pH 8.0, 0.15 M 
NaCl, 2% glycerol by weight, 1.0 mg/mL lysozyme, 0.2 mg/mL DNase, 300 µL/well) was added 
to the cell pellet and lysis was performed by incubating 4 h at 4 °C,150 rpm. The plate was 
centrifuged (4000´g, 4 °C, 10 min) and 150 µL of lysate were transferred with an automated liquid 
handling workstation to 96-well plate containing 10 µL styrene stock solution (15 mM final 
concentration in DMSO) and 250 µL NADPH/ADH stock solution (2 mM NADPH final 
concentration, 1 U/mL final conc. for ADH from Sigma Aldrich No. 49461). The plate was 
incubated for 1.5 h at 23 °C, 200 rpm. The reactions were diluted with 600 µL acetonitrile and 
incubated for 30 min at room temperature. The plate was centrifuged (4000 g, 4 °C, 5 min) and 
150 µL of the supernatant were transferred to a 96-well assay plate. The amount of phenylethanol 
and styrene oxide was analyzed using analytical HPLC. 90 variants per site-saturation library were 
screened. 
(E) Large scale expression of P450 variants. E. coli BL21(DE3) cells transformed with 
plasmid encoding P450 variants were grown overnight in 5 mL Luria-Bertani medium (100 ug mL-
 6 
1 ampicillin final concentration) at 37 ºC, 250 rpm. Expression cultures were inoculated with 5 mL 
of preculture into 500 mL Terrific Broth medium (100 µg mL-1 ampicillin final concentration) in a 
2 L flask and incubated for 4 h at 37 ºC, 125 rpm. The flask was cooled on ice for 10 min before 
expression was induced (0.2 mM IPTG, 0.5 mM aminolevulinic acid, final concentration). Induced 
cells were shaken for 20 h at 25 ºC, 125 rpm. The cells were harvested (4500´g, 5 min, 4 ºC) and 
stored at -20 °C.  
(F) Bioconversions and determination of total turnover numbers. Styrene was 
converted in an enzyme cascade together employing the P450 variant and alcohol dehydrogenase 
to determine the performance of each variant (total turnover number and anti-Markovnikov 
selectivity). Because aldehydes are prone to side reaction in buffered systems, we chose to combine 
our P450 with an alcohol dehydrogenase to prevent aldehyde accumulation by direct reduction to 
the corresponding alcohol. E. coli BL21(DE3) cells were lysed with lysis buffer (0.1 M NaH2PO4, 
pH 8.0, 0.15 M NaCl, 2% glycerol by weight, 1.0 mg/mL lysozyme, 0.2 mg/mL DNase) for 4 h on 
ice followed by centrifugation (30 min, 4000´g, 4 °C). The supernatant was used as lysate in the 
bioconversion reactions of styrene and other substrates. The concentration of P450 enzymes in 
lysate was determined from ferrous carbon monoxide binding difference spectra using the 
previously reported protocol (48). For bioconversions, 50 µL of lysate (approx. 0.3 µM P450 final 
conc.) were mixed with 742 µL NADP+ buffer solution (0.1 M NaH2PO4, pH 8.0, 0.15 M NaCl, 
2% glycerol by weight, 1 mM NADP+ final conc.) containing 10 U ADH (Sigma Aldrich No. 
49461) and 1 % isopropanol for NADPH cofactor regeneration. 8 µL substrate stock in DMSO 
(5 mM final substrate conc.) were added to start the reaction in 2 mL screw-top glass vials. The 
bioconversion was stopped by adding 800 µL acetonitrile after incubating 2 h at room temperature 
(400 rpm). The sample was incubated for 30 min at room temperature, centrifuged for 5 min. 
(14000´g, 25 °C) and the supernatant was analyzed by analytical HPLC. Calibration curves were 
determined for quantitative HPLC analysis using commercially available, authentic standards. The 
total turnover numbers (TTN) were calculated as ratio of product and P450 concentrations. The 
anti-Markovnikov selectivity was calculated by conc. alcohol / (conc. alcohol + conc. epoxide). 
The reactions were performed in triplicate from at least two biological replicates. For chiral GC 
measurements, the reaction was stopped after 2 h by extracting two times with 500 µL ethyl acetate, 
combined and used for analysis. 
(G) P450LA1 purification. E. coli BL21(DE3) cells were lysed with lysis buffer (3 mL / g 
cell pellet, 0.1 M NaH2PO4, pH 8.0, 0.15 M NaCl, 10% glycerol by weight, 10 mM imidazole, 1.0 
mg/mL lysozyme, 0.2 mg/mL DNase) for 4 h on ice followed by centrifugation (35 min, 20,000´g, 
4 °C). The protein containing a C-terminal 6xHis-tag was purified by loading the supernatant on a 
nickel NTA column (1 mL HisTrap HP, GE Healthcare, Piscataway, NJ) using an AKTA purifier. 
The column was washed with 4 column volumes buffer A (0.1 M NaH2PO4, pH 8.0, 0.15 M NaCl, 
10% glycerol by weight, 10 mM imidazole) and the protein was eluted using a linear gradient from 
100% buffer A to 100% buffer B (0.1 M NaH2PO4, pH 8.0, 0.15 M NaCl, 10% glycerol by weight, 
10 mM imidazole) over 10 column volumes. The combined fractions were dialyzed with 3 L buffer 
(0.1 M NaH2PO4, pH 8.0, 0.15 M NaCl, 10% glycerol by weight) and concentrated. 50 µL aliquots 
were frozen using liquid nitrogen and stored and -20°C. 
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III. Supporting Figs. S1 to S11 




Catalytic protocols for anti-Markovnikov oxidation follow three major strategies: a modified 
Wacker oxidation, a dehydrogenative oxygenation approach, and a tandem epoxidation 
isomerization cascade. Strictly speaking, the tandem epoxidation-isomerization cascade is not a 
direct anti-Markovnikov oxidation. This cascade proceeds in a sequential manner via an epoxide 
intermediate that is rearranged in a second step. All current protocols either depend on precious 
metals performing with low turnover numbers (29, 49–60) often combined with substrates bearing 
directing groups (58–60), do not offer enantiocontrol (29, 49–63), utilize complex catalysts that 
require multistep synthesis (56, 61) and/or use stoichiometric amounts of terminal oxidants such 
as iodosylbenzene which generate stoichiometric amounts of waste (29, 49, 55, 57, 59–62). 
Catalysts that use earth-abundant metals for aerobic direct anti-Markovnikov oxidation are 









The anti-Markovnikov selectivity in this reaction is most likely a consequence of the relative 
energies of the high-energy intermediates in the catalytic cycle. The anti-Markovnikov reaction 
proceeds via the more stabilized secondary carbocation / radical intermediates. Markovnikov 
selectivity could be achieved via the less-stabilized primary carbocation / radical intermediates. 




Fig. S3 The P450LA1-catalyzed anti-Markovnikov oxidation is a direct oxidation without an 
epoxide intermediate. 
 
(A) GC chromatogram after conversion of styrene with P450LA1. The reaction yields the 
corresponding phenylacetaldehyde 2 and styrene oxide 3. (B) Same reaction as A, but in the 
presence of an alcohol dehydrogenase (ADH). The ADH reduces phenylacetaldehyde 2 to the 
corresponding 2-phenylethanol 2-Alc and recycles the cofactor by isopropanol oxidation. 
Chromatograms in (C) and (D) are derived from the conversion of (R)- and (S)-styrene oxide. 
Neither epoxide enantiomer was converted using the P450LA1 ADH cascade, thus demonstrating 
that epoxides are not substrates for P450LA1 and not intermediates in the catalytic cycle. Thus, 
P450LA1 catalyzes a direct anti-Markovnikov oxidation and not an epoxidation-isomerization 
sequence as suggested previously (18). 
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Fig. S4 Purpald assay for high-throughput colorimetric aldehyde quantification. 
 
 
(A) The Purpald reagent (47) was used to quantify aldehyde concentration in high-throughput. 
Purpald forms a cyclic aminal with aldehydes that rapidly get oxidized to the corresponding purple-
colored tetrazine. (B) The UV/VIS spectrum of the tetrazine product shows a maximum at 538 nm, 
which was used as the absorbance wavelength in the assay. (C) Tetrazine formation, measured as 
absorbance (538 nm), shows linear dependence on the phenylacetaldehyde concentration. 
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The structure of the P450LA1 heme domain was predicted using I-Tasser (64), SWISS-MODEL 
(65) and Phyre2 (66). The P450LA1 heme domain has low sequence identity (<50%) with 
structurally characterized P450s. The structure prediction tools generated models based on the 
structures of the P450 monooxygenase PikC (PDB ID: 2WHW) (67) and a P450 from Streptomyces 
peucetius (PDB ID: 5IT1) (68). The mutations identified in the screening of random mutagenesis 
libraries are distributed over the heme domain (T121A, N201K, N209S, Y385H and E418G). All 
five mutations contribute to the improved activity, but only the T121A mutation, believed to be in 
the active site based on these homology models, significantly enhanced selectivity for the anti-
Markovnikov product (from 45% to 55%). These homology models were used to identify potential 
active site amino acids for iterative site-saturation mutagenesis (21). The following potential active 
site amino acids were mutated and screened during the course of laboratory evolution: L97, A103, 
Y116, A117, M118, N119, R120, A121, M122, V123I, N124, H206, S207, A275, V278, S325, 
I326, V327, W329, R330, S428 and F429 (see Table S2 for more details). In addition, the highly 
conserved amino acids of the heme binding site (Cys ligand loop) were targeted for site-saturation 
mutagenesis: F383, G384, Y385 (H385 in P450LA1 wild type), G386, S387, H388, Q389, M391, 
G392 and K393. 
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P450LA1 wild type did not show any epoxide aldehyde isomerization activity (see Fig. S3). To 
prove that laboratory evolution did not generate isomerization activity, the corresponding (R)- and 
(S)-epoxides were incubated with aMOx using the standard biotransformation protocol. This 
standard protocol includes an alcohol dehydrogenase and cofactor recycling system to reduce the 
generated aldehyde to the corresponding alcohol 2-alc. Since neither the (R)- nor the (S)-epoxide 
enantiomer were converted under these conditions, the epoxide is not an intermediate of the 
catalytic cycle. (A) HPLC chromatogram of a sample (blue) containing phenylethanol 2-Alc and 
styrene oxide 3 is compared to the biotransformation of (R)-3 (red). No aldehyde or alcohol 
formation was observed. (B) HPLC chromatogram of a sample (blue) containing phenylethanol 2-
Alc and styrene oxide 3 is compared to the biotransformation of (S)-3 (red). No aldehyde or alcohol 
formation was observed.  
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Conversion of styrene 1 with aMOx. Since aldehydes are prone to side reactions in water, the 
aldehyde product of the aMOx reaction was directly converted to the corresponding alcohol 2-alc 
using an enzyme cascade with an alcohol dehydrogenase (ADH). The ADH has dual function in 
that it also recycles the NADPH cofactor by isopropanol oxidation. The time course of the reaction 
demonstrates constant product selectivity for 2-Alc and 3 (yellow triangles), which supports the 
proposed mechanism of direct anti-Markovnikov oxidation without an epoxide intermediate. 
Reaction conditions: 2 mM alkene, 1.0 µM aMOx, 10 units ADH, 1% i-PrOH, 0.2 equiv. NADP+, 








To confirm that a 1,2-hydride shift is part of the aMOx cycle, deuterium-labeled styrene 4 was used 
as substrate. Since aldehydes are prone to racemization in buffered medium, the aldehyde product 
5 of the aMOx step was directly converted to the corresponding alcohol 5-alc using an enzyme 
cascade with an alcohol dehydrogenase. The deuterated styrene 4 showed conversion and anti-
Markovnikov selectivity identical to the non-deuterated styrene. The isolated alcohol product 5-alc 
was analyzed by NMR and compared to a commercial standard without deuterium label. The 
1H NMR spectrum of the isotopically labeled alcohol product clearly shows an integral of only one 
H at the benzylic position (see NMR spectra below). In addition, the 13C NMR spectra reveal a 
triplet for the benzylic carbon which is in accordance with C-D coupling. 
For the biotransformation, 4.2 mL E. coli lysate (for preparation see general procedures, 0.25 µM 
final aMOx conc.) were mixed with 81.2 mL NADP+ buffer solution (0.1 M NaH2PO4, pH 8.0, 
0.15 M NaCl, 2% glycerol by weight, 500 µM NADP+ final conc.), containing 600 U ADH (Sigma 
Aldrich No. 49461) and 1 % isopropanol for NADPH cofactor regeneration. 0.85 µL styrene-b,b-
d2 substrate stock in DMSO (5 mM final substrate conc.) were added to start the reaction. The 
bioconversion was incubated 1 h at 23°C (200 rpm). The crude product was extracted with 75 mL 
of a 1:1 mixture ethyl acetate / n-hexane (three times). The combined organic phase was dried with 
MgSO4 and the solvent was removed under reduced pressure. The isolated oil was purified by with 
column chromatography using silica gel (ethyl acetate : n-hexane = 1:10 to 1:4, v:v) to yield 5-alc 
(7.5 mg, 14%) as colorless oil. 1H NMR (300 MHz, CDCl3) d 7.45-7.27 (m, 2H), 7.29-7.06 (m, 
3H), 3.88-3.81 (m, 1H), 2.90-2.82 (t, J = 6.4 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ 138.39, 








(A) Proposed mechanism for the anti-Markovnikov oxidation of alkenes. Since isotopic labeling 
confirmed a 1,2-hydride migration as part of the catalytic cycle, we propose that the stereocenter 
is generated by controlling the enantioselectivity of the 1,2-migration. The enzyme can achieve 
this by locking the substrate in a specific conformation that pre-aligns the orbitals for the 
carbocation 1,2-rearrangement. This suprafacial 1,2-shift (grey box) is believed to proceed in a 
concerted fashion (25, 44). (B) Traces of chiral gas chromatography analyses are compared. 
Racemic mixture (top), enzymatic trans-formation at pH 8.0 (middle) and enzymatic 
transformation at pH 7.4 (bottom). The reactions were performed as described for the anti-
Markovnikov redox hydrations with the following changes: NADH was used in equimolar 
concentration to the substrate (5 mM) in the absence of alcohol dehydrogenase to prevent aldehyde 
reduction. The reactions were stopped after 10 minutes to avoid racemization of the stereocenter 
in the buffered solution. The reactions at pH 7.4 revealed a higher enantioselectivity, most likely 








The anti-Markovnikov oxygenase (aMOx) can be viewed as the key enzyme in an enzymatic or 
microbial platform for various challenging anti-Markovnikov functionalization reactions (3). We 
have demonstrated that aMOx can be combined with alcohol dehydrogenases to catalyze anti-
Markovnikov redox hydrations. Since carbonyl compounds are substrates for many biocatalysts, 
various anti-Markovnikov functionalization reactions of alkenes can be envisioned by constructing 
synthetic metabolic pathways or de novo multi-enzyme cascades (27, 69). (a) alcohol 
dehydrogenases (70); (b) aldehyde dehydrogenases or aldehyde oxidases (71, 72); (c) w-
transaminases or imine reductases (35, 73); (d) imine reductases, reductive aminase or pictet 




Fig. S11 Examples of additional substrates tested for anti-Markovnikov redox hydration using 






The anti-Markovnikov redox hydration of the styrenes Sty-1-3 showed product formation with low 
to moderate selectivity for the primary alcohol (see HPLC chromatograms). The peaks labeled with 
asterisk correspond most likely to the epoxide oxidation product. No product formation could be 
observed with Sty-4 as substrate. The reactions were performed using our standard conditions (see 
section F in general procedures). Because aMOx is fully genetically encoded, the catalyst can be 
readily optimized by further directed evolution to expand the substrate scope.  
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IV. Supporting Tables S1 to S3 
Table S1 Summary of known catalytic examples for direct and sequential anti-Markovnikov 
oxidation of alkenes. 




















Styrene H4[PMo11VO40] 1.2 equiv. 
PdCl2 






















5 mol% <20 88-99 (60) 











AgNO2 or NaNO2 
5-6 mol% 





























1-2 mol% <100 -- (55) 
Styrenes O2* 
Ru(IV)-porphyrin 









































6-20 -- (63) 
*Aerobic anti-Markovnikov oxidation of alkenes depend on precious Pd/Ru catalysts. 
† anti-Markovnikov selectivity (in comparison to Markovnikov selectivity). 
‡ Substrate controlled anti-Markovnikov selectivity.  
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Table S2 Summary of directed evolution for alkene anti-Markovnikov oxidation. 
Round Parent Library Mutations identified 
1 P450LA1 wild type 
Random mutagenesis of the heme 
domain 





2 P450LA1 wild type 
Recombination of hits identified 




3 N201K, Y385H, T121A 
Random mutagenesis of the heme 
domain 
3.5 mutations / 1000 bp 
N209S 
4 N201K, Y385H, T121A, N209S 
Random mutagenesis of the heme 
domain 
2.5 mutations / 1000 bp 
E418G 
5 N201K, Y385H, T121A, N209S, E418G 
Site-saturation mutagenesis 




6 N201K, Y385H, T121A, N209S, E418G, V123I, I326V 
Site-saturation mutagenesis 
M118X, S207X, A275X, V278X M118L 
7 N201K, Y385H, T121A, N209S, E418G, V123I, I326V, M118L,  
Site-saturation mutagenesis 
A117X, N119X, R120X, 
M122X, N124X, S325X 
R120H 
8 
N201K, Y385H, T121A, N209S, 
E418G, V123I, I326V, M118L, 
R120H, V327M 
Site-saturation mutagenesis 
Y116X, V327X, R330X, S428X V327M 
9 
N201K, Y385H, T121A, N209S, 
E418G, V123I, I326V, M118L, 
R120H, V327M 
Site-saturation mutagenesis 
L97X, A103X A103L 
10A N201K, Y385H, T121A, N209S, E418G, V123I, I326V 
Site-saturation mutagenesis 
F383X, G384X, H385X, G386X, 








N201K, Y385H, T121A, N209S, 
E418G, V123I, I326V, M118L, 
R120H, V327M, A103L 
Combination of mutations 
identified in 10A into final 






Table S3 Activity of P450 variants generated by directed evolution for the anti-Markovnikov 
oxidation of styrene. 
 
Round Variant TON ± SD Anti-Markovnikov selectivity (calc. as % alcohol product) 
Parent P450LA1 wild type 99 ± 5 45 
1A N201K, Y385H 190 ± 0 45 
1B T121A, I198M 390 ± 15 55 
2 N201K, Y385H, T121A 520 ± 2 55 
3 N201K, Y385H, T121A, N209S 750 ± 7 55 
4 (= P7) 
N201K, Y385H, T121A, N209S, 
E418G 1200 ± 50 54 
5 N201K, Y385H, T121A, N209S, E418G, V123I, I326V 1600 ± 167 62 
6 N201K, Y385H, T121A, N209S, E418G, V123I, I326V, M118L 1800 ± 24 68 
7 
N201K, Y385H, T121A, N209S, 
E418G, V123I, I326V, M118L, 
R120H 
2500 ± 51 72 
8 
N201K, Y385H, T121A, N209S, 
E418G, V123I, I326V, M118L, 
R120H, V327M 
3500 ± 126 76 
9 
N201K, Y385H, T121A, N209S, 
E418G, V123I, I326V, M118L, 
R120H, V327M, A103L 
3700 ± 78 78 
10 (aMOx) 
N201K, T121A, N209S, E418G, 
V123I, I326V, M118L, R120H, 
V327M, A103L, M391L, H385V 
3800 ± 99 81 
 
• Round 1 to 4 are based on colorimetric screening of random mutagenesis libraries of the heme domain using 
the Purpald assay. 
• Round 5 to 10 are based on HPLC screening of libraries generated by site-saturation mutagenesis. 
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V. NMR spectra of the isotopic labeling experiment 
(a) 1H NMR spectra comparison of 2-phenylethanol (standard) and 2-phenylethanol-1,2-d2. 




























































































































(b) 13C NMR spectra comparison of 2-phenylethanol (standard) and 2-phenylethanol-1,2-d2. 











































































































VI. Preparative scale reactions 
 
General protocol. To optimize the system for high conversion, we worked with a reduced substrate 
loading (2 mM final concentration) that enabled efficient cofactor recycling with the current setup. 
Purified aMOx (1.0 µM final conc., 0.05 mol% catalyst) was mixed in a flask with NADP+ (0.4 mM 
final conc., 0.2 equivalents), alcohol dehydrogenase (10 U/mL, Sigma Aldrich, 49641) and alkene 
(2 mM final conc., 100 mM stock solution in 1:1 DMSO and isopropanol) in a phosphate buffer 
system (100 mM sodium phosphate, pH 8.0, 150 mM NaCl, 2.0% glycerol). Preparative scale 
reactions were performed with 40 and 60 mg starting material (0.23 – 0.50 mmol scale). The 
reactions were carried out in 500 mL flasks by incubating the mixture for 2 h at room temperature 
(120 rpm). The reaction was extracted with ethyl acetate/hexanes 4:1 (three times, 100 mL, 50 mL 
and 35 mL). The combined organic layers were washed with water (20 mL) and brine (20 mL), 
dried over MgSO4, filtered, concentrated, and purified by column chromatography. 
 
 
2-(4-Chlorophenyl)ethanol (8): The reaction was performed on 0.25-mmol scale. The product was 
purified by column chromatography (9 – 20% ethyl acetate/hexanes). Isolated 35.9 mg (82% yield, 
1600 TTN). 1H NMR (300 MHz, CDCl3): δ 7.30–7.26 (m, 2H), 7.17–7.14 (m, 2H), 3.83 (t, 
J = 6.5 Hz, 2H), 2.83 (t, J = 6.5 Hz, 2H), 1.66 (s, 1H); 13C NMR (75 MHz, CDCl3): δ 137.14, 
132.38, 130.47, 128.76, 63.56, 38.57. 
 
2-[4-(Trifluoromethyl)phenyl]ethanol (9): The reaction was performed on 0.23-mmol scale. The 
product was purified by column chromatography (9 – 20% ethyl acetate/hexanes). Isolated 31.3 mg 
(73% yield, 1500 TTN). 1H NMR (300 MHz, CDCl3): δ 7.57 (d, J = 8.1 Hz, 2H), 7.35 (d, J = 8.1 Hz, 
2H), 3.89 (t, J = 6.5 Hz, 2H), 2.93 (t, J = 6.5 Hz, 2H), 1.59 (s, 1H); 13C NMR (101 MHz, CDCl3): 
δ 142.96 (q, J = 1.2 Hz), 129.48, 128.95 (q, J = 32.4 Hz), 125.56 (q, J = 3.8 Hz), 124.45 (q, 
J = 271.9 Hz), 63.38, 39.05; 19F NMR (282 MHz, CDCl3): δ -62.45. 
 
(S)-1-Phenyl-2-propanol (16): The reaction was performed on 0.50-mmol scale. The product was 
purified by column chromatography (9 – 20% ethyl acetate/hexanes). Isolated 19.1 mg (28% yield, 
560 TTN, >99:1 er). 1H NMR (300 MHz, CDCl3): δ 7.35–7.20 (m, 5H), 4.07–3.98 (m, 1H), 2.80 
(dd, J = 13,4, 4,9 Hz, 1H), 2.69 (dd, J = 13,4, 7,9 Hz, 1H), 1.59 (s, 1H), 1.25 (d, J = 6.2 Hz, 3H); 




VII. NMR spectra for preparative scale reactions 
1H NMR: 2-(4-chlorophenyl)ethanol (8) 
 
 















































































































1H NMR: 2-[4-(trifluoromethyl)phenyl]ethanol (9) 
 
 




















































































































19F NMR: 2-[4-(trifluoromethyl)phenyl]ethanol (9) 
 
 





























































































































































































VIII. HPLC calibration curves 
(a) HPLC calibration: External standard calibration curves were created for quantitative HPLC 
analysis using commercial standards.  
 
(b) Calibration curves for styrene, 2-phenylethanol and styrene oxide at 210 nm. 
 
 
(c) Calibration curves for 4-chlorostyrene, 2-(4-chlorophenyl)ethanol and 2-(4-





(d) Calibration curves for 4-(trifluoromethyl)styrene, 2-[4-(trifluoromethyl)phenyl]ethanol and 2-




(e) Calibration curves for 3-chlorostyrene, 2-(3-chlorophenyl)ethanol and 2-(3-





(f) Calibration curves for 4-methylstyrene, 2-(4-methylphenyl)ethanol and 2-(4-




(g) Calibration curves for 4-bromostyrene, 2-(4-bromophenyl)ethanol and 2-(4-





(h) Calibration curves for 3-(trifluoromethyl)styrene, 2-[3-(trifluoromethyl)phenyl]ethanol and 2-




(i) Calibration curves for 2-(trifluoromethyl)styrene, 2-[2-(trifluoromethyl)phenyl]ethanol and 2-




(j) Calibration curves for  a-methylstyrene, 2-phenyl-1-propanol and 2-methyl-2-phenyloxirane 




(k) Calibration curves for trans-b-methylstyrene, 1-phenyl-2-propanol and trans-2-methyl-3-





IX. HPLC traces for anti-Markovnikov redox hydration 
(a) Product identities were confirmed by retention time and additionally by HPLC co-injections of 
reaction mixtures with standard molecules. The recovery of the starting material was calculated for 
each run and was between 92.5 and 106.9%. The average recovery was 98.7%. The reactions are 
not optimized for conversion at this stage. Depending on the substrate, conversions of 5.5 to 45% 
were achieved in these proof-of- concept biocatalytic anti-Markovnikov redox hydrations. 
Representative HPLC traces are shown below. 
 
(b) Product ratio as analyzed by HPLC for the anti-Markovnikov redox hydration of 4-
chlorostyrene measured at 210 nm. 
 
 
(c) Product ratio as analyzed by HPLC for the anti-Markovnikov redox hydration of 4-




(d) Product ratio as analyzed by HPLC for the anti-Markovnikov redox hydration of 3-




(e) Product ratio as analyzed by HPLC for the anti-Markovnikov redox hydration of 4-





(f) Product ratio as analyzed by HPLC for the anti-Markovnikov redox hydration of 4-




(g) Product ratio as analyzed by HPLC for the anti-Markovnikov redox hydration of 3-





(h) Product ratio as analyzed by HPLC for the anti-Markovnikov redox hydration of 2-




(i) Product ratio as analyzed by HPLC for the anti-Markovnikov redox hydration of a-
methylstyrene measured at 210 nm (the peak at 2.5 min corresponds to the allylic oxidation 




(j) Product ratio as analyzed by HPLC for the anti-Markovnikov redox hydration of trans-b-




(k) Product ratio as analyzed by HPLC for the anti-Markovnikov redox hydration of styrene 










The figures show chiral GC traces for anti-Markovnikov redox hydration of a-methylstyrene (left) 
and b-methylstyrene (right). Each figure shows the products of enzymatic conversion (red) in 
comparison to the racemic standard (blue). 
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XI. NMR characterization and spectra of standard compounds 
 
Characterization of reaction products. Authentic standards corresponding to enzymatic 
reaction products were bought from Sigma or custom synthesized by TCI America. All products 
are known compounds, and their spectral data are in agreement with reported values.(79–84) 
 
2-Phenylethanol: 1H NMR (300 MHz, CDCl3): δ 7.35–7.21 (m, 5H), 3.86 (t, J =6.6 Hz, 2H), 2.87 
(t, J = 6.6 Hz, 2H), 1.54 (s, 1H); 13C NMR (75 MHz, CDCl3): δ 138.60, 129.16, 128.70, 126.59, 
63.80, 39.32. 
 
2-(4-chlorophenyl)ethanol (8): 1H NMR (300 MHz, CDCl3): δ 7.30–7.26 (m , 2H), 7.18–7.14 (m, 
2H), 3.83 (t, J = 6.5 Hz, 2H), 2.83 (t, J = 6.6 Hz, 2H), 1.55 (s, 1H); 13C NMR (75 MHz, CDCl3): δ 
137.14, 132.38, 130.48, 128.77, 63.56, 38.58. 
 
2-[4-(trifluoromethyl)phenyl]ethanol (9): 1H NMR (300 MHz, CDCl3): δ 7.57 (d, J = 8.0 Hz, 
2H), 7.35 (d, J = 8.0 Hz, 2H), 3.88 (t, J = 6.5 Hz, 2H), 2.92 (t, J = 6.5 Hz, 2H), 1.56 (s, 1H); 13C 
NMR (101 MHz, CDCl3): δ 142.96 (q, J = 1.2 Hz), 129.47, 128.92 (q, J = 32.4 Hz), 125.56 (q, 
J = 3.8 Hz), 124.45 (q, J = 273.71 Hz), 63.36, 39.04; 19F NMR (282 MHz, CDCl3): δ -62.45. 
 
2-(3-chlorophenyl)ethanol (10): 1H NMR (300 MHz, CDCl3): δ 7.27–7.19 (m, 3H), 7.13–7.09 
(m, 1H), 3.85 (q, J = 6.3 Hz, 2H), 2.84 (t, J = 6.5 Hz, 2H), 1.54 (t, J = 5.5 Hz, 1H); 13C NMR 
(75 MHz, CDCl3)i: δ 140.79, 134.42, 129.90, 129.24, 127.35, 126.78, 63.43, 38.91. 
 
2-(4-methylphenyl)ethanol (11): 1H NMR (300 MHz, CDCl3): δ 7.13 (s, 4H), 3.84 (q, J = 6.3 Hz, 
2H), 2.83 (t, J = 6.6 Hz, 2H), 2.34 (s, 3H), 1.50 (t, J = 5.6 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 
136.13, 135.40, 129.40, 129.03, 63.90, 38.86, 21.15. 
 
2-(4-bromophenyl)ethanol (12): 1H NMR (300 MHz, CDCl3): δ 7.45–7.41 (m, 2H), 7.13–7.08 
(m, 2H), 3.83 (q, J = 6.4 Hz, 2H), 2.81 (t, J = 6.5 Hz, 2H), 1.52 (t, J = 5.7 Hz, 1H); 13C NMR 
(75 MHz, CDCl3): δ 137.68, 131.73, 130.88, 120.43, 63.49, 38.65. 
 
2-[3-(trifluoromethyl)phenyl]ethanol (13): 1H NMR (300 MHz, CDCl3): δ 7.50 – 7.47 (m, 2H), 
7.45 – 7.41 (m, 2H), 3.88 (q, J = 6.4 Hz, 2H), 2.93 (t, J = 6.5 Hz, 2H), 1.56 (t, J = 5.6 Hz, 1H); 13C 
NMR (75 MHz, CDCl3): δ 139.75, 132.59 (q, J = 1.5 Hz), 130.96 (q, J = 32.1 Hz), 129.05, 125.83 
(q, J = 3.8 Hz), 123.46 (q, J = 3.8 Hz), 122.48, 63.40, 39.01; 19F NMR (282 MHz, CDCl3) δ -62.62. 
 
2-[2-(trifluoromethyl)phenyl]ethanol (14): 1H NMR (300 MHz, CDCl3): δ 7.66–7.64 (m, 1H), 
7.51–7.30 (m, 3H), 3.87 (t, J = 6.8 Hz, 2H), 3.07 (t, J = 6.8 Hz, 2H), 1.61 (s, 1H); 13C NMR 
(75 MHz, CDCl3): δ 137.04 (q, J = 1.7 Hz), 131.81, 131.71, 128.94 (q, J = 29.7 Hz), 126,53, 126.16 
(q, J = 5.8 Hz), 124.54 (q, J = 273.7 Hz), 63.27, 35,93; 19F NMR (282 MHz, CDCl3) δ -59.44. 
 
2-phenyl-1-propanol (15): 1H NMR (300 MHz, CDCl3): δ 7.37–7.21 (m, 5H), 3.70 (d, J = 6.8 Hz, 
2H), 2.95 (q, J = 6.9 Hz, 1H), 1.47 (s, 1H), 1.28 (d, J = 7.0 Hz, 3H). 13C NMR (75 MHz, CDCl3): 
δ 143.77, 128.76, 127.61, 126.80, 68.84, 42.56, 17.71.  
 
1-phenyl-2-propanol (16): 1H NMR (300 MHz, CDCl3): δ 7.35–7.20 (m, 5H), 4.07–3.98 (m, 1H), 
2.80 (dd, J = 13,4, 4,9 Hz, 1H), 2.69 (dd, J = 13,4, 7,9 Hz, 1H), 1.59 (s, 1H), 1.25 (d, J = 6.2 Hz, 
3H); 13C NMR (75 MHz, CDCl3): δ 138.62, 129.52, 128.68, 126.62, 69.01, 45.92, 22.92.   
 40 
1H NMR 2-Phenylethanol 
 
 
















































































































1H NMR: 2-(4-chlorophenyl)ethanol (8) 
 
 







































































































1H NMR: 2-[4-(trifluoromethyl)phenyl]ethanol (9) 
 
 















































































































































1H NMR: 2-(3-chlorophenyl)ethanol (10) 
 
 



























































































































1H NMR: 2-(4-methylphenyl)ethanol (11) 
 
 































































































1H NMR: 2-(4-bromophenyl)ethanol (12) 
 
 



























































































































1H NMR: 2-[3-(trifluoromethyl)phenyl]ethanol (13) 
 
 



















































































































































































1H NMR: 2-[2-(trifluoromethyl)phenyl]ethanol (14) 
 
 





















































































































































































1H NMR: 2-phenyl-1-propanol (15) 
 
 





















































































































1H NMR: 1-phenyl-2-propanol (16) 
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